Trial Profile
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Apatorsen (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms Borealis-1
- Sponsors Achieve Life Sciences; OncoGenex Pharmaceuticals; OncoGenex Technologies
- 01 Oct 2017 Primary endpoint (Overall survival) has not been met as per the results published in the Annals of Oncology
- 01 Oct 2017 Results published in the Annals of Oncology
- 12 Nov 2015 According to an OncoGenex media release, results from this trial will be presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC 2015).